肝硬化和肝癌尿激酶型纤溶酶原激活物及受体检测的意义
出处
《检验医学》
CAS
北大核心
2010年第4期330-331,共2页
Laboratory Medicine
参考文献8
-
1Kruger A, Soeltl R, Lutz V, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor ( CD87 ) [J]. Cancer Gene Ther, 2000, 7(2) : 292-299.
-
2Nakata S, Ito K, Fujimori M, et al. Involvenment of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers[J]. IntJCancer, 1998, 79(2): 179-186.
-
3Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes [J]. Blood, 1998, 91(7): 2305-2312.
-
4OzakiY.血栓止血领域[J].内科,2000,86(6):1094-1094.
-
5Zhang LP, Takahara T, Yata Y, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats : role of stellate cells [ J ]. J Hepatol, 1999, 31(4): 703-711.
-
6Salgado S, Garcia J, Vera J, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy[J]. Mol Ther, 2007, 2(6) : 545-551.
-
7闵军,陈孝平,陈积圣,吴在德,裘法祖.原发性肝癌尿激酶和尿激酶受体表达的研究[J].中华实验外科杂志,2000,17(5):395-397. 被引量：6
-
8Chan CFG, Yah YO, Jin DW, et al. Evalution of nuclear factor- kappa B, urokenasy-type plasminogen activator, and HBx and their clinical pathological significance in hepatocellular carcinoma[J]. Clin Cancer, 2007, 15(10): 41404149.
二级参考文献5
-
1Andreasen PA,Kjoller L,Christensen L,et al.The urokinase-type plasminogen activator system in cancer metastasis: a review[].International Journal of Cancer.1997
-
2Reuning U,Magdolen V,Wilhelm O,et al.Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review)[].International Journal of Oncology.1998
-
3Kroon ME,Koolwijk P,van Goor H,et al.Role and localization of urokinase receptor in the formation of new microvascula rstructures in fibrin matrices[].American Journal of Pathology.1999
-
4Duffy MJ,Maguire TM,McDermott EW,et al.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer[].Journal of Surgical Oncology.1999
-
5Foekens JA,Peters HA,Look MP,et al.The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients[].Cancer Research.2000
共引文献6
-
1李明昌,石忠松,夏之柏,黄正松.颅内动脉瘤细胞外基质相关基因表达谱的基因芯片研究[J].中华实验外科杂志,2005,22(7):855-857. 被引量：13
-
2周欢琴,陈刚,卢兴国,叶雄伟.急慢性乙型肝炎患者血浆uPA和uPAR的检测及意义[J].中华实验和临床病毒学杂志,2006,20(3):238-240. 被引量：2
-
3奕泉根,谢国栋,张桂娣,卢兴国.肝癌组织浸液尿激酶型纤溶酶原激活物及其受体的初步实验研究[J].中国实验诊断学,2007,11(1):118-119.
-
4张虹,周欢琴,翁秀妹,卢兴国,朱杰.肝病患者血浆MMP-3、TIMP-1、u-PA和u-PAR水平的临床研究[J].中国卫生检验杂志,2010,20(1):107-109. 被引量：2
-
5周欢琴,张虹,翁秀妹,卢兴国,朱杰,王强,范芳华.肝硬化和肝癌患者血浆MMP-3、TIMP-1、u-PA和u-PAR水平与临床关系的研究[J].浙江检验医学,2009,0(2):36-38. 被引量：4
-
6卢岑,石胜,梁浓亮,王小朝,熊燕.原发性肝癌患者血浆uPA和suPAR的临床研究[J].医师进修杂志,2004,27(6):21-22. 被引量：2
-
1钱超,曹真虎.淋巴瘤患者血浆尿激酶型纤溶酶原激活物及其受体检测的临床意义[J].检验医学,2010,25(2):157-158.
-
2卢兴国,毛建山,蔡红军,刘进,王彩花,王炜琴,朱蕾.胸腹水纤溶系统的研究及其意义[J].中华血液学杂志,2001,22(3):149-150. 被引量：9
-
3王爱民,黄儒飞.肿瘤患者凝血及纤溶分子标志物的变化[J].新疆医科大学学报,2008,31(7):887-888. 被引量：2
-
4盛礼建,卢兴国.中枢神经系统感染患者血浆尿激酶型纤溶酶原激活物及其受体检测的意义[J].检验医学,2009,24(12):916-918.
-
5张林生,汪坤镕,谢锦西,温博贵.转铁蛋白受体检测及其临床意义[J].国外医学（临床生物化学与检验学分册）,1992,13(6):252-255. 被引量：3
-
6詹灵凌,吕小平,李国坚,李山,唐劲光,王健.肝硬化患者血浆uPA、uPAR水平与纤溶和凝血功能的相关性[J].临床检验杂志,2010,28(1):31-32.
-
7罗玉琴.尿激酶型纤溶酶原激活物及其受体检测的应用[J].上海医学检验杂志,2002,17(6):377-378. 被引量：4
-
8高志波,陈彬,钱令涛,郭红军,谢兰军.自制简易三通脑室外引流装置[J].安徽医学,2010,31(1):73-73.
-
9蔡后荣,沈国荣.可溶性白细胞介素2受体检测在肺部疾病中的临床意义[J].临床荟萃,1995,10(4):148-149.
-
10夏志鹏,王振义.可溶性白细胞介素_2受体检测在某些疾病中的意义[J].国外医学（临床生物化学与检验学分册）,1991,12(5):200-202. 被引量：1
